UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Phase I study of the orally administered butyrate prodrug, tributyrin, in patients with solid tumors

Clinical cancer research, 1998-03, Vol.4 (3), p.629-634

1998

Volltextzugriff (PDF)

XMT-1001, A Novel Biodegradable Polyacetal Polymer Conjugate of Camptothecin in Clinical Development

Current bioactive compounds, 2011-03, Vol.7 (1), p.15-20

2011

Volltextzugriff (PDF)

Intravenous pamidronate disodium treatment of bone metastases in patients with breast cancer. A dose‐seeking study

Cancer, 1994-12, Vol.74 (11), p.2949-2955

1994

Volltextzugriff (PDF)

Subasumstat, a first-in-class inhibitor of SUMO-activating enzyme, demonstrates dose-dependent target engagement and SUMOylation inhibition, leading to rapid activation of innate and adaptive immune responses in the dose escalation portion of a phase 1/2 clinical study

European journal of cancer (1990), 2022-10, Vol.174, p.S125-S126

2022

Volltextzugriff (PDF)

Characterization of acquired resistance to cis-diamminedichloroplatinum(II) in BE human colon carcinoma cells

Cancer research (Chicago, Ill.), 1990, Vol.50 (1), p.72-77

1990

Volltextzugriff (PDF)

Mismatch repair of cis-diamminedichloroplatinum(II)-induced DNA damage

Molecular pharmacology, 1985-07, Vol.28 (1), p.51

1985

Volltextzugriff (PDF)

Cisplatin and platinum analogues: recent advances

Current opinion in oncology, 1992-12, Vol.4 (6), p.1073-1079

Fram, Robert j

1992

Volltextzugriff (PDF)

Preirradiation chemotherapy of supratentorial malignant primary brain tumors with intracarotid cis-platinum (CDDP) and i.v. BCNU : a phase II trial

American journal of clinical oncology, 1990-04, Vol.13 (2), p.125-131

1990

Volltextzugriff (PDF)

Inhibition of DNA excision repair and the repair of X-ray-induced DNA damage by cytosine arabinoside and hydroxyurea

Pharmacology & therapeutics (Oxford), 1985, Vol.31 (3), p.165-176

1985

Volltextzugriff (PDF)

Lethal effects of 1-beta-D-arabinofuranosylcytosine incorporation into deoxyribonucleic acid during ultraviolet repair

Molecular pharmacology, 1984-03, Vol.25 (2), p.322-326

1984

Volltextzugriff (PDF)

Schedule dependence of buthionine sulfoximine in reversing resistance to cisplatin

Chemico-biological interactions, 1990, Vol.76 (3), p.333-342

1990

Volltextzugriff (PDF)

Effect of 1-β- D-arabinofuranosyl cytosine and hydroxyurea on the repair of X-ray-induced DNA single-strand breaks in human leukemic blasts

Biochemical pharmacology, 1985-07, Vol.34 (14), p.2557-2560

1985

Volltextzugriff (PDF)

Potentiation of ara-C induced cytotoxicity by hydroxyurea in LoVo colon carcinoma cells

Biochemical pharmacology, 1987-05, Vol.36 (10), p.1673-1677

1987

Volltextzugriff (PDF)

Sequence specificity of streptozotocin-induced mutations

Nucleic acids research, 1988-10, Vol.16 (20), p.9811-9820

1988

Volltextzugriff (PDF)

Gene expression caused by alkylating agents and cis-diamminedichloroplatinum(II) in Escherichia coli

Cancer research (Chicago, Ill.), 1988-09, Vol.48 (17), p.4823-4826

1988

Volltextzugriff (PDF)

Bone metastases

Medicine and health, Rhode Island, 2000-04, Vol.83 (4), p.112

2000

Volltextzugriff (PDF)

Phase I study of XMT-1001 given IV every 3 weeks to patients with advanced solid tumors

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.e13121-e13121

2010

Volltextzugriff (PDF)

A phase I study of the safety and pharmacokinetics (PK) of XMT-1001 given as an intravenous (IV) infusion once every three weeks to patients with advanced solid tumors

Journal of clinical oncology, 2009-05, Vol.27 (15_suppl), p.2574-2574

2009

Volltextzugriff (PDF)

A Phase I Study of the Dolastatin-15 Analogue Tasidotin (ILX651) Administered Intravenously Daily for 5 Consecutive Days Every 3 Weeks in Patients with Advanced Solid Tumors

Clinical cancer research, 2005-11, Vol.11 (21), p.7807-7816

2005

Volltextzugriff (PDF)

Phase I and Pharmacokinetic Study of the Dolastatin-15 Analogue Tasidotin (ILX651) Administered Intravenously on Days 1, 3, and 5 Every 3 Weeks in Patients with Advanced Solid Tumors

Clinical cancer research, 2005-11, Vol.11 (21), p.7825-7833

2005

Volltextzugriff (PDF)

A phase I study of a CanAg-targeted immunoconjugate, huC242-DM4, in patients with Can Ag-expressing solid tumors

Journal of clinical oncology, 2007-06, Vol.25 (18_suppl), p.3062-3062

2007

Volltextzugriff (PDF)

Studies on mutagenesis and repair induced by platinum analogs

Mutation research, 1986, Vol.173 (1), p.13-18

1986

Volltextzugriff (PDF)

DNA strand breaks caused by inhibitors of DNA synthesis: 1-beta-D-arabinofuranosylcytosine and aphidicolin

Cancer research (Chicago, Ill.), 1982-10, Vol.42 (10), p.4050-4054

1982

Volltextzugriff (PDF)

Accumulation of leukemic cell DNA strand breaks with adriamycin and cytosine arabinoside

Leukemia research, 1983, Vol.7 (2), p.243-249

1983

Volltextzugriff (PDF)

Genetic control of ligand-induced events in B lymphocytes

The Journal of immunology (1950), 1976-11, Vol.117 (5 Pt 1), p.1456-1463

1976

Volltextzugriff (PDF)

1 – 25 von 160

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(131)
Mit Volltextzugriff
(127)

Publikationsform

Sprache

Englisch
(158)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Phase I study of the orally administered butyrate prodrug, tributyrin, in patients with solid tumors

XMT-1001, A Novel Biodegradable Polyacetal Polymer Conjugate of Camptothecin in Clinical Development

Intravenous pamidronate disodium treatment of bone metastases in patients with breast cancer. A dose‐seeking study

Subasumstat, a first-in-class inhibitor of SUMO-activating enzyme, demonstrates dose-dependent target engagement and SUMOylation inhibition, leading to rapid activation of innate and adaptive immune responses in the dose escalation portion of a phase 1/2 clinical study

Characterization of acquired resistance to cis-diamminedichloroplatinum(II) in BE human colon carcinoma cells

Mismatch repair of cis-diamminedichloroplatinum(II)-induced DNA damage

Cisplatin and platinum analogues: recent advances

Preirradiation chemotherapy of supratentorial malignant primary brain tumors with intracarotid cis-platinum (CDDP) and i.v. BCNU : a phase II trial

Inhibition of DNA excision repair and the repair of X-ray-induced DNA damage by cytosine arabinoside and hydroxyurea

Lethal effects of 1-beta-D-arabinofuranosylcytosine incorporation into deoxyribonucleic acid during ultraviolet repair

Schedule dependence of buthionine sulfoximine in reversing resistance to cisplatin

Effect of 1-β- D-arabinofuranosyl cytosine and hydroxyurea on the repair of X-ray-induced DNA single-strand breaks in human leukemic blasts

Potentiation of ara-C induced cytotoxicity by hydroxyurea in LoVo colon carcinoma cells

Sequence specificity of streptozotocin-induced mutations

Gene expression caused by alkylating agents and cis-diamminedichloroplatinum(II) in Escherichia coli

Bone metastases

Phase I study of XMT-1001 given IV every 3 weeks to patients with advanced solid tumors

A phase I study of the safety and pharmacokinetics (PK) of XMT-1001 given as an intravenous (IV) infusion once every three weeks to patients with advanced solid tumors

A Phase I Study of the Dolastatin-15 Analogue Tasidotin (ILX651) Administered Intravenously Daily for 5 Consecutive Days Every 3 Weeks in Patients with Advanced Solid Tumors

Phase I and Pharmacokinetic Study of the Dolastatin-15 Analogue Tasidotin (ILX651) Administered Intravenously on Days 1, 3, and 5 Every 3 Weeks in Patients with Advanced Solid Tumors

A phase I study of a CanAg-targeted immunoconjugate, huC242-DM4, in patients with Can Ag-expressing solid tumors

Studies on mutagenesis and repair induced by platinum analogs

DNA strand breaks caused by inhibitors of DNA synthesis: 1-beta-D-arabinofuranosylcytosine and aphidicolin

Accumulation of leukemic cell DNA strand breaks with adriamycin and cytosine arabinoside

Genetic control of ligand-induced events in B lymphocytes

Suchergebnisse filtern